Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tenofovir Disoproxil Fumarate

FDA-approved product (tablet, oral), marketed as Tenofovir Disoproxil Fumarate, Viread.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tenofovir Disoproxil Fumarate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis B virus infection
  • Hepatitis B virus infection
  • HIV infection
  • HIV-1 infection
  • Infection
  • Liver disease
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF07

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA30.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli40.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tenofovir Disoproxil Fumarate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tenofovir Disoproxil Fumarate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Randomized Controlled Trial on the Efficacy of Tenofovir Disoproxil Fumarate (TDF)-Switch Therapy in Chronic Hepatitis B Patients With Incomplete Response to Entecavir

    NCT01918631 · start 2013-08

    Registered record
    Registry ID
    NCT01918631
    Conditions
    Chronic Heptitis B
    Interventions
    tenofovir disoproxil fumarate; Entecavir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-08
    Completion
    2017-01-31
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Heptitis B
    Interventiontenofovir disoproxil fumarate; Entecavir
    PhaseNot applicable
    Registry statusCompleted

  • Factors Affecting PrEP Adherence

    NCT02411630 · start 2013-06

    Registered record
    Registry ID
    NCT02411630
    Conditions
    HIV Infection
    Interventions
    Emtricitabine/tenofovir disoproxil
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-06
    Completion
    2015-06
    Enrolment
    167

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionEmtricitabine/tenofovir disoproxil
    PhaseNot recorded
    Registry statusCompleted

  • A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects

    NCT01850212 · start 2013-02

    Registered record
    Registry ID
    NCT01850212
    Conditions
    HIV Infections
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-02
    Completion
    2014-10
    Enrolment
    476

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy

    NCT01694017 · start 2012-11

    Registered record
    Registry ID
    NCT01694017
    Conditions
    HIV
    Interventions
    Tenofovir; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-11
    Completion
    2014-08
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionTenofovir; Zidovudine
    PhasePhase 4
    Registry statusCompleted

  • Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

    NCT01533259 · start 2012-01

    Registered record
    Registry ID
    NCT01533259
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    Stribild
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-01
    Completion
    2013-07
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionStribild
    PhasePhase 3
    Registry statusCompleted

  • Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

    NCT01495702 · start 2011-12

    Registered record
    Registry ID
    NCT01495702
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    NNRTI; FTC/TDF; Stribild
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-12
    Completion
    2014-12
    Enrolment
    439

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionNNRTI; FTC/TDF; Stribild
    PhasePhase 3
    Registry statusCompleted

  • Effects of Intensive cART During Acute/Early HIV Infection

    NCT01154673 · start 2011-11

    Registered record
    Registry ID
    NCT01154673
    Conditions
    Acute HIV Infection
    Interventions
    raltegravir; maraviroc; emtricitabine 200mg /tenofovir 300mg; lopinavir 400 mg/ritonavir 100mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2011-11
    Completion
    2014-09
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute HIV Infection
    Interventionraltegravir; maraviroc; emtricitabine 200mg /tenofovir 300mg; lopinavir 400 mg/ritonavir 100mg
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue

    NCT01480284 · start 2011-11

    Registered record
    Registry ID
    NCT01480284
    Conditions
    Hepatitis B, Chronic
    Interventions
    GSK548470 300 mg tablet; ETV 0.5 mg capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-11
    Completion
    2014-11
    Enrolment
    166

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B, Chronic
    InterventionGSK548470 300 mg tablet; ETV 0.5 mg capsule
    PhasePhase 3
    Registry statusCompleted

  • Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB

    NCT01320943 · start 2011-04-26

    Registered record
    Registry ID
    NCT01320943
    Conditions
    Chronic Hepatitis B
    Interventions
    TDF; Stop TDF
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-04-26
    Completion
    2016-08-23
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionTDF; Stop TDF
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)

    NCT01300234 · start 2011-03-30

    Registered record
    Registry ID
    NCT01300234
    Conditions
    Hepatitis B
    Interventions
    Tenofovir disoproxil fumarate (TDF) tablets; Adefovir dipivoxil (ADV) tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-03-30
    Completion
    2016-12-06
    Enrolment
    512

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B
    InterventionTenofovir disoproxil fumarate (TDF) tablets; Adefovir dipivoxil (ADV) tablets
    PhasePhase 3
    Registry statusCompleted

  • Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries

    NCT01061151 · start 2011-03-01

    Registered record
    Registry ID
    NCT01061151
    Conditions
    HIV Infections
    Interventions
    Zidovudine (ZDV); Nevirapine (NVP): Antepartum Mothers; Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail; Lamivudine-Zidovudine (3TC-ZDV); Lopinavir-ritonavir (LPV-RTV); Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]); Nevirapine (NVP): Infant short-course; Nevirapine (NVP): Infant extended; No Intervention; Discontinue triple ARVs; Continue triple ARVs
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-03-01
    Completion
    2016-09-30
    Enrolment
    3,747

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionZidovudine (ZDV); Nevirapine (NVP): Antepartum Mothers; Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail; Lamivudine-Zidovudine (3TC-ZDV) +7 more
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

    NCT00799864 · start 2011-01

    Registered record
    Registry ID
    NCT00799864
    Conditions
    HIV-1
    Interventions
    Rilpivirine; Zidovudine; Abacavir; Tenofovir disoproxil fumarate; Lamivudine; Emtricitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-01
    Completion
    2022-08
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1
    InterventionRilpivirine; Zidovudine; Abacavir; Tenofovir disoproxil fumarate +2 more
    PhasePhase 2
    Registry statusCompleted

  • Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men

    NCT01140880 · start 2010-05

    Registered record
    Registry ID
    NCT01140880
    Conditions
    HIV Seroconversion; Stimulant Abuse
    Interventions
    Truvada
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-05
    Completion
    2013-03
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Seroconversion; Stimulant Abuse
    InterventionTruvada
    PhasePhase 2
    Registry statusCompleted

  • Hepatitis B Surface Antigen(HBsAg) Loss in Chronic Hepatitis B Patients With Low Viral Load

    NCT00973219 · start 2009-09

    Registered record
    Registry ID
    NCT00973219
    Conditions
    Chronic Hepatitis B
    Interventions
    Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-09
    Completion
    2019-10
    Enrolment
    151

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionPeg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate
    PhaseNot applicable
    Registry statusCompleted

  • Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment

    NCT00737724 · start 2008-03

    Registered record
    Registry ID
    NCT00737724
    Conditions
    HIV; AIDS; Tuberculosis
    Interventions
    Simultaneous ARV and antiMTB; Deferred RV and antiMTB treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2008-03
    Completion
    2011-02
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; AIDS; Tuberculosis
    InterventionSimultaneous ARV and antiMTB; Deferred RV and antiMTB treatment
    PhaseNot applicable
    Registry statusTerminated